Zions Bancorporation National Association UT Takes $960,000 Position in Certara, Inc. (NASDAQ:CERT)

Key Points

• Zions Bancorporation National Association UT has acquired a new position in Certara, Inc., purchasing 96,966 shares valued at approximately $960,000.
• Certara's stock has seen a decline of 2.8% and currently trades at $10.94, with a market capitalization of $1.76 billion.
• Analysts have mixed ratings on Certara, with a consensus rating of "Moderate Buy" and a target price of $15.14, reflecting uncertainty in its future performance.

Zions Bancorporation National Association UT acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 96,966 shares of the company's stock, valued at approximately $960,000. Zions Bancorporation National Association UT owned 0.06% of Certara as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in CERT. The Manufacturers Life Insurance Company lifted its stake in Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after acquiring an additional 823 shares during the period. Private Advisor Group LLC lifted its stake in Certara by 4.0% in the first quarter. Private Advisor Group LLC now owns 24,517 shares of the company's stock worth $243,000 after acquiring an additional 949 shares during the period. Wells Fargo & Company MN lifted its stake in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the period. Bank of Montreal Can lifted its stake in Certara by 9.1% in the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after acquiring an additional 1,670 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after acquiring an additional 1,866 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Down 2.8%

Certara stock opened at $10.94 on Friday. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 218.84 and a beta of 1.42. The stock has a 50 day moving average of $10.93 and a two-hundred day moving average of $11.76. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a return on equity of 5.11% and a net margin of 1.97%. The firm had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. During the same period in the prior year, the firm posted $0.07 earnings per share. The business's revenue for the quarter was up 12.1% compared to the same quarter last year. As a group, research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on CERT shares. KeyCorp decreased their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Monday, July 14th. UBS Group reduced their price objective on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a report on Thursday. Morgan Stanley assumed coverage on Certara in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 target price on the stock. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Finally, Barclays raised Certara from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Certara presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.14.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.